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Abstract: Natural products still constitute a prolific source of lead compounds for the development of novel drugs. 
Due to their unmatched structural diversity they represent an indispensable complement to synthetic compound 
collections and virtual libraries. However, the tremendous changes which have taken place in the drug discovery 
process over the last decade have introduced completely new requirements for natural product research. The 
classical bioactivity-guided approach no longer matches the timelines and the workflow of modern drug discovery. 
More targeted approaches are needed in order to identify promising candidate molecules at an early stage, and to 
accelerate the follow-up process. We describe herein our strategy for tracking bioactive components in complex 
mixtures, and discuss the potential of accurate mass measurements for natural product identification and the im-
pact of mass-controlled preparative HPLC on the isolation process of bioactive compounds.
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pound libraries, there has been a steady in-
troduction of natural product-derived drugs 
in the last years. According to a recent 
review [3], a total of 15 natural products 
or natural product-derived drugs has been 
launched in either the United States, Europe 
or Japan in the years 2000–2003. Among 
these are essential medicines such as the 
anti-malaria drug arteeether (Artemotil®), 
galanthamine (Reminyl®) for the treatment 
of Alzheimer’s disease, and pimecrolimus 
(Elidel®) for atopic dermatitis. The impact 
of natural products on the development 
pipelines of the pharmaceutical industry is 
unabated. As per December 2003, some 15 
compounds were in phase III clinical trials 
or registration, including representatives of 
novel compound classes such as the anti-
cancer drug ixabepilone, a semisynthetic 
derivative of epothilone B produced by the 
myxobacterium Sorangium cellulosum. 
Ziconotide, the synthetic equivalent of 
ω-conotoxin found in the dart venom of the 
cone shell Conus magus, was approved by 
the FDA in December 2004 for the treat-
ment of chronic pain [4]. 
One of the most striking features of nat-
ural products is their unmet and still largely 
untapped structural diversity. In the post-
genomic era with its increasing number of 
druggable targets, natural products remain 
a rather indispensable complement to syn-
thetic compound collections. Natural prod-
ucts in particular are sterically more com-
plex and differ from synthetic compounds 
with respect to the statistical distribution 
of functionalities [5]. They cover a much 
larger volume of the chemical space and 
display a broader dispersion of structural 
and physicochemical properties than com-
pounds issued from combinatorial synthesis 
[6]. However, the accelerated transforma-
tion of the drug discovery process which 
has taken place over the last decade has put 
completely new requirements on natural 
product research. In particular, the classi-
cal and historically successful approach 
of screening crude or pre-purified extracts 
followed by several iterative steps of activ-
ity-guided fractionation [7] does not match 
with the short target cycle times in HTS, 
where testing capacities are only provided 
for a limited time window. As further pit-
falls, the loss of bioactivity in the course of 
the purification process is not uncommon, 
and there is little means for early derepli-
cation of known or otherwise uninteresting 
compounds. There is clearly a compelling 
need for faster and more effective strategies, 
delivering early information on the bioac-
tive constituents, and compatible with the 
modern drug discovery workflow. 
HPLC-based Activity Profiling 
Natural product extracts are highly 
complex mixtures containing hundreds to 
thousands of constituents, among which 
only one or just a few are responsible for 
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Introduction
Natural products have traditionally played a 
major role in drug discovery and still con-
stitute a prolific source of novel lead com-
pounds for medicinal chemistry. About 40% 
of current prescription drugs are directly or 
indirectly derived from compounds of bio-
genic origin [1][2]. Molecules originating 
from natural products leads are well repre-
sented among the 35 top selling prescription 
drugs worldwide, with percentages ranging 
from approximately 20 to 40% over the last 
five years. Despite increasing competition 
from combinatorial and classical com-
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the pharmacological properties. Probably 
the most challenging task in this context 
is to combine biological data and chemo-
analytical information in a judicious man-
ner in order to identify the active principles 
at an early stage [8]. The generalization 
of miniaturized and highly sensitive as-
says has recently opened new possibilities. 
HPLC-based activity profiling is one of the 
most successful approaches, and is widely 
used in our laboratory for tracking bioactive 
compounds in crude mixtures. It consists of 
fractionating bioactive extracts in 96-for-
mat by means of analytical or semiprepara-
tive HPLC and subsequently assessing the 
bioactivity of each fraction. In this way, the 
activity can be assigned to chromatographic 
peaks and correlated with the spectroscopic 
information available on-line. The principle 
is shown in Fig. 1. An extract is separated 
by analytical gradient HPLC. Via a T-split, a 
portion of the effluent is fractionated in the 
96-well format, while the other part serves 
for the on-line spectroscopic characteriza-
tion of the eluted peaks. After drying, the 
fractions are redissolved in a small amount 
of a suitable solvent, typically DMSO, and 
assayed for bioactivity. The activity profile 
is then matched with the HPLC chromato-
gram and the spectroscopic data recorded 
on-line. A targeted preparative isolation is 
subsequently carried out if the active prin-
ciples are deemed of sufficient interest. As 
a major asset, the microfractionation step 
can be performed with the bioactive sample 
stored in the library, without the need for 
macroscopic isolation nor time-consuming 
refermentation or recollection activities, 
and the associated issues of unsatisfac-
tory reproducibility. Preparative purifica-
tion is then performed using a straight-
forward peak-guided strategy which does 
not require biological testing after each 
chromatographic step. The scale-up of 
the separation is straightforward, since 
the chromatographic system can be easily 
transposed to preparative scale. Compared 
to other innovative setups which have been 
recently developed for the on-line integra-
tion of biological and chemo-analytical 
systems [8][9], HPLC-based profiling is 
particularly versatile and directly applica-
ble to a broad range of mechanism-based 
and cellular assays. For this reason, it has 
also become the method of choice in indus-
trial natural product screening programs.
Fig. 2 shows an application of this ap-
proach in the course of a screening program 
for novel glucagon receptor antagonists. An 
extract of Streptomyces sp. strongly inhib-
ited glucagon-induced cAMP elevation. 
Semipreparative gradient HPLC separation 
of 30 μl of extract into 30 one-minute frac-
tions and subsequent testing of each frac-
tion enabled the activity to be attributed to 
the main peak at 16.1 min. HPLC-UV-MS 
analysis revealed a UV-spectrum similar to 
Fig. 1. Schematic representation of HPLC-based extract profiling
Fig. 2. Activity profiling for glucagon receptor inhibitory activity in a streptomycete extract: Activity 
plot, HPLC/MS/UV analysis and structure of the bioactive constituent [10]
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and high-throughput dereplication of com-
pounds remains challenging when no pre-
liminary information is available. Not all 
spectroscopic data are equally well suited 
to database searching. Moreover, full inte-
gration of spectroscopic data of different 
types and formats remains unsatisfactory. 
The molecular formula, which can be 
deduced from an accurate mass determi-
nation, is one of the most useful pieces of 
information for searching large databases 
such as CAS Registry. It can now be rou-
tinely obtained with time of flight (TOF) 
mass spectrometers which are increasing-
ly used for HPLC-MS analysis of natural 
products [12][13]. TOF mass spectrometry 
combines high accuracy with high sensitiv-
ity due to high-frequency sampling of all 
ions simultaneously in the full mass range. 
By using an external reference, which can 
be introduced into the source in alternation 
with the analyte through a second spray 
(lockspray), accuracy down to ca. 3 ppm 
can be routinely achieved.
While nominal mass and fragmenta-
tion information provided by quadrupole 
instruments often proves to be difficult to 
use for database searching and is insuffi-
cient for compound identification, the mass 
accuracy obtained by HPLC-ESI-TOF-MS 
enables one to calculate a limited number 
of elemental composition hypotheses. By 
combining this information with additional 
data (UV spectral data, taxonomy of the 
producer), identification of a large number 
of known substances is possible. Moreover, 
accurate mass and, as a corollary, molecu-
lar formula are well suited to automated 
database searching, a condition for high-
throughput dereplication.
The identification of indirubin in a 
crude extract of the orchid Calanthe tricari-
nata (Orchidaceae) is shown as an example 
of this approach. By using a lockspray de-
vice, two separate chromatograms were 
recorded for the analyte and the reference 
compounds, respectively (Fig. 3). The mass 
observed for the pseudomolecular [M+H]+ 
ion of the peak at 17.44 min (263.079 amu) 
was corrected with the data simultaneously 
recorded for the external reference linco-
mycin. A search in the Dictionary of Natu-
ral Products (DNP) database (Chapman & 
Hall) with the accurate mass of 262.072 
amu and a mass tolerance of 10 ppm gave 
a match list of only nine compounds. In-
clusion of the UV spectral data then unam-
biguously identified indirubin (Fig. 4).
Preparative HPLC-MS
HPLC-based activity profiling in con-
junction with hyphenated spectroscopic 
methods enables promising compounds to 
be tracked in crude extracts, and often their 
chemical structures can be determined on-
Fig. 3. Lockspray HPLC-ESI TOF MS analysis of indirubin in a crude extract of Calanthe tricarinata 
(Orchidaceae). The accurate mass of indirubin is determined by correcting the measured mass with 
the expected values for lincomycin (407.2216) or erythromycin (734.4690).
Fig. 4. Identification of induribin from the accurate MS and UV data with the Dictionary of Natural 
Products (Chapman & Hall)
that of tryptophan and a MW of 2036 amu. 
Since no record corresponding to these data 
could be found in the literature, purification 
of the compound was undertaken on a pre-
parative scale. The compound, a new bicy-
clic peptide, exhibited potent and selective 
antagonist activity towards the human glu-
cagon receptor in a functional assay (IC50 
0.44 μM) [10]. In this project, the micro-
scale fractionation also reliably filtered out 
other extracts in which the inhibitory activ-
ity could be assigned to known compounds 
of little interest, such as cephalochromin or 
resistomycin.
On-line Accurate Mass 
Measurements and Database 
Search
In recent years, the impact of HPLC-
coupled spectroscopy on natural product 
analysis has been tremendous. The con-
certed use of HPLC-DAD, -MS and -NMR 
has opened entirely new possibilities for the 
characterization of secondary metabolites 
in biological extracts. These techniques 
provide a wealth of structural information 
on-line from minute amounts of sample 
[11]. Nevertheless, rapid identification 
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fungus Stilbella sp. is shown in Fig. 6 as an 
example [14]. The four compounds could 
be obtained in a spectroscopically pure 
form in a single step. Up to 32 mg of the 
fraction could be separated per chromato-
graphic run. Mass triggered detection al-
lowed optimal fraction cutting even when 
some compounds gave asymmetric and in-
completely resolved peaks.
Conclusion
The approaches described here are part 
of numerous innovative technological de-
velopments which have taken place during 
the last decade [8]. The unique diversity of 
natural products and their successful track 
record are undisputed. However, continu-
ing improvements will be needed if natural 
products research should keep pace with 
the ongoing changes in drug discovery, in 
particular with the unbroken trend towards 
miniaturization and shorter project cycle 
times. Further improvement in combining 
chemoanalytical and biological data, and full 
automation of the dereplication process are 
probably the greatest challenges for the next 
few years. In view of recent achievements 
and ongoing developments it is reasonable 
to think that, despite increased competition 
from synthetic and virtual libraries, natural 
products will remain an invaluable source of 
new pharmaceuticals in the future.
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Fig. 5. Typical preparative HPLC-MS setup
Fig 6. Preparative HPLC-MS separation of four terphenylquinones from a crude fraction of the fungus 
Stilbella sp. [14]. C18 column (30 × 100 mm i.d.), 0.02% aq. AcOH-MeCN (28:72), flow rate: 28 ml/min, 
applied amount: 32 mg in 0.5 ml MeOH. Fractions collected automatically are highlighted.
line without requiring any time- and cost-
consuming isolation work. However, pre-
parative isolation remains indispensable 
for detailed biological characterization of 
potential lead compounds. The emergence 
of mass spectrometry-controlled prepara-
tive HPLC has recently led to a paradigm 
change in preparative chromatography. The 
high sensitivity and selectivity of mass de-
tection enables a highly efficient purifica-
tion of compounds directly from complex 
matrices, even when they are present only 
as minor components. Since this technol-
ogy is well suited to automation and un-
attended operation, large autopurification 
platforms combining both mass and UV 
triggering modes have been set up, in par-
ticular in the context of industrial drug dis-
covery. A typical setup is shown in Fig. 5. 
The eluent is split after the HPLC column 
in a ratio of 1:1000 to 1:5000 between the 
collection and detection lines. A make-up 
pump is used to create a sufficient flow in 
the detection line and dilute the eluent in or-
der to avoid detector saturation. The delay 
between detection and collection (typically 
10–25 s) is then determined as a function 
of the flow rate. The DAD detector and the 
mass spectrometer can be coupled in paral-
lel, as shown in the Fig., or in series. When 
the target mass signal exceeds a given 
threshold, a three-way valve, triggered by 
the mass spectrometer, switches the eluent 
flow from the waste line to the fraction col-
lector. For additional specificity, mass and 
UV collection criteria can be combined us-
ing the logical operators ‘and’, ‘and not’, 
and ‘or’.
The purification of four terphenylqui-
nones with src inhibiting activity from the 
MS-triggered 3-ways valve
